VitroScreen has been a pioneer in developing and proposing pre-clinical experimental protocols on 3D reconstructed human tissue models: they are currently applied to demonstrate the mechanism of action of SBMD and they are relevant to comply with the safety and efficacy requirements of the EU MDR 2017/745.
The seminar has the ambition to open a discussion on MDCG 2022-5 with stakeholders involved in Medical Devices (Health Authorities, Notified Bodies, Academia, Industry and ISO representative) analyzing the state of the art of scientific approaches to qualification and classification issues.
To view the program and instruction for registration, please, click here.